SparingVision to Highlight Progress of its SPVN20 Program in oral presentation at ASGCT 2023
Paris, April 27, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces today that it has been selected for an oral presentation at ASGCT 26th Annual Meeting in Los Angeles, 16-20 May 2023.
Hanen Khabou, Ph.D., Senior Scientist at SparingVision will present in vitro and in vivo data supporting the potential of its second lead gene-agnostic gene therapy program, SPVN20, aimed at restoring vision in later-stage retinitis pigmentosa patients.
Oral Presentation: Development of a mutation-independent gene therapy for cone reactivation in the treatment of Retinitis Pigmentosa
Date and Time: Saturday May 20, 2023, 09:00AM- 09:15AM, Room 502 AB
Presenter: Hanen Khabou, Ph.D.
Session Title: Ophthalmic and Auditory Diseases
Session Number: 344
**ENDS**